Subcellular MLH1 protein as first in class biomarker for CDK4/6 response in endocrine resistant ER+/HER2-breast cancer

被引：0
|
作者：
Mazumder, Aloran
Oropeza, Elena
Punturi, Nindo
Haricharan, Svasti
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5129
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5129
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Therapy of advanced HR+, HER2-Breast Cancer Live professionally longer with CDK4/6 Inhibitor
    Ruedesheim, Sabine M.
    BREAST CARE, 2021, 16 (03)
  • [42] Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC)
    Velimirovic, Marko
    Gerratana, Lorenzo
    Davis, Andrew A.
    Hensing, Whitney L.
    Clifton, Katherine
    Shah, Ami N.
    D'Amico, Paolo
    Dai, Charles S.
    Denault, Elyssa N.
    Ma, Cynthia X.
    Wander, Seth A.
    Juric, Dejan
    Cristofanilli, Massimo
    Chabner, Bruce A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [43] Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
    Bahnassy, Shaymaa
    Stires, Hillary
    Jin, Lu
    Tam, Stanley
    Mobin, Dua
    Balachandran, Manasi
    Podar, Mircea
    Mccoy, Matthew D.
    Beckman, Robert A.
    Riggins, Rebecca B.
    ENDOCRINOLOGY, 2023, 164 (12) : 1 - 15
  • [44] The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2-metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors
    Kamaraju, Sailaja
    Fowler, Amy
    Cheng, Chung Yee
    Chaudhary, Lubna N.
    Burfeind, John
    Retseck, Janet
    Tevaarwerk, Amye J.
    Burkard, Mark
    Paplomata, Elisavet
    Parkes, Amanda M.
    Jorns, Julie M.
    Tarima, Sergey
    Yee, Douglas
    Rui, Hallgeir
    Lange, Carol
    Sahmoud, Tarek
    Wisinski, Kari B.
    CANCER RESEARCH, 2022, 82 (04)
  • [45] Glucose Metabolic Reprogramming of ER+ Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Mannelli, Michele
    Parri, Matteo
    Comito, Giuseppina
    Ippolito, Luigi
    Giannoni, Elisa
    Bonechi, Martina
    Benelli, Matteo
    Migliaccio, Ilenia
    Malorni, Luca
    Chiarugi, Paola
    Morandi, Andrea
    CELLS, 2020, 9 (03)
  • [46] Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2-breast cancer
    Ragusi, Max A. A.
    Winter-Warnars, Gonneke A. O.
    Wesseling, Jelle
    Linn, Sabine C.
    Beets-Tan, Regina G.
    van der Velden, Bas H. M.
    Elias, Sjoerd G.
    Gilhuijs, Kenneth G. A.
    Loo, Claudette E.
    BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1123):
  • [47] MRI Patterns in the evaluation of pathological response after Neoadjuvant Endocrine therapy in ER+/HER2-Breast Cancer and Implications on Surgical Planning
    Nakad, B.
    Milevsky, D.
    Simovici, P.
    Brodsky, A.
    BREAST, 2023, 68 : S57 - S58
  • [48] CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2-advanced breast cancer with impending or established visceral crisis
    Behrouzi, Roya
    Armstrong, Anne C.
    Howell, Sacha J.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (01) : 83 - 95
  • [49] CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
    Roya Behrouzi
    Anne C. Armstrong
    Sacha J. Howell
    Breast Cancer Research and Treatment, 2023, 202 : 83 - 95
  • [50] Endoxifen Downregulates AKT Phosphorylation Through Protein Kinase C Beta 1 in ER+/HER2-Breast Cancer
    Jayaraman, Swaathi
    Wu, Xinyan
    Kalari, Krishna R.
    Tang, Xiaojia
    Kuffel, Mary
    Bruinsma, Elizabeth S.
    Renuse, Santosh
    Ingle, James N.
    Reid, Joel
    Schellenberg, Matthew
    Hawse, John
    Pandey, Akhilesh
    Goetz, Matthew P.
    CANCER RESEARCH, 2023, 83 (05)
12345